Sickle Cell Disease Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Sickle Cell Disease Epidemiology Forecast Report Coverage

Expert Market Research's “Sickle Cell Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of sickle cell disease. It projects the future incidence and prevalence rates of sickle cell disease cases across various populations. The study covers age, gender, and type as major determinants of the sickle cell disease population. The report highlights patterns in the prevalence of sickle cell disease over time and projects future trends based on multiple variables.

Sickle Cell Disease Understanding: Disease Overview

Sickle cell disease (SCD) is a hereditary hemoglobinopathy resulting from a mutation in the β-globin gene, leading to production of abnormal hemoglobin S. Under low oxygen conditions, red blood cells become rigid and sickle-shaped, causing vaso-occlusion, hemolytic anemia, and organ damage. The condition manifests in several genotypes, including HbSS, HbSC, and HbSβ-thalassemia, with variable severity. SCD predominantly affects individuals of African, Middle Eastern, and Indian ancestry and is associated with recurrent pain crises, stroke, and increased infection risk.

Sickle Cell Disease Epidemiology Perspective

The sickle cell disease epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the sickle cell disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for sickle cell disease and their trends. The sickle cell disease detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• From 2000 to 2021, the total incidence of sickle cell disease affected babies has risen by 13.7%, globally. The number of people living with sickle cell disease has increased by 41.4%.
• As of 2021, approximately 7.74 million people worldwide were living with sickle cell disease. The prevalence is highest in sub-Saharan Africa, where nearly 80% of global cases are concentrated.
• In 2021, there were an estimated 515,000 new births with sickle cell disease globally, primarily in sub-Saharan Africa.
• A systematic analysis from the Global Burden of Disease Study 2021 reported an all-age prevalence of sickle cell disease among females at 3.90 million, which is similar to the all-age prevalence among males.

Read more about this report - Request a Free Sample

Country-wise Sickle Cell Disease Epidemiology Segment

The sickle cell disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, sickle cell disease (SCD) affects approximately 100,000 individuals, predominantly non-Hispanic Black or African American. It occurs in about 1 in 365 Black or African American births and 1 in 16,300 Hispanic American births. The disease significantly reduces life expectancy, with affected individuals living over 20 years less than the general population. Challenges in accessing routine healthcare, preventive screenings, and recommended treatments contribute to health disparities. Early diagnosis, comprehensive care, and equitable access to therapies are essential to improve outcomes and reduce morbidity and mortality in the U.S.

The World Health Organization indicates that around 4.5-5% of the entire world population exhibit the traits of hemoglobinopathies. In India, the incidence of sickle cell anemia lies between 1-44%. The mean prevalence is around 3.3% across the country, with approximately 30 million carriers.

Sickle Cell Disease: Treatment Overview

Treatment for sickle cell disease focuses on preventing complications and managing vaso-occlusive crises. Hydroxyurea remains the main disease-modifying therapy, promoting fetal hemoglobin production and reducing crises. Blood transfusions are used to prevent stroke and severe anemia. Newer agents such as voxelotor, crizanlizumab, and L-glutamine improve hemoglobin stability and reduce inflammation. Curative options include allogeneic hematopoietic stem cell transplantation and emerging gene-editing therapies. Supportive care with vaccination, pain management, and infection prophylaxis is critical for long-term survival and quality of life.

Key Questions Answered

• What are the key findings of sickle cell disease epidemiology in the 8 major markets?
• What will be the total number of patients with sickle cell disease across the 8 major markets during the forecast period?
• What was the country-wise sickle cell disease epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of sickle cell disease during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of sickle cell disease during the forecast period of 2026-2035?
• What are the currently available treatments for sickle cell disease?
• What are the disease risks, signs, symptoms, and unmet needs of sickle cell disease?

Scope of the Sickle Cell Disease Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of sickle cell disease based on several factors.
• Sickle Cell Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The sickle cell disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Sickle Cell Disease Treatment Market

Sickle Cell Disease Drug Pipeline Analysis